AprilBio Amends Paid-In Capital Increase Report for Convertible Preferred Shares, Changes Third-Party Allottee to SPC
This amendment corrects the third-party allotment entity in the paid-in capital increase decision report filed on June 25, 2026.
The original allottee IMM Asset Management was replaced by IMM Healthcare No. 8 LLC, an SPC established by the private equity fund IMM Healthcare PEF.
IMM Scale-Up Bio No. 1 LLC remains as an allottee, maintaining the total issuance of 1,222,254 convertible preferred shares unchanged.
Key terms including the issue price of 40,908 won per share, full 1-year lock-up, and intended use of 50 billion won for R&D expenses are all preserved.
The correction is an administrative step to enhance legal clarity of the transaction structure and has no material impact on existing shareholder value.
[AI Summary]This amendment by AprilBio is procedural and does not alter the economic terms of the capital increase. The 3.8% dilution from convertible preferred shares is mitigated by a 1-year lock-up and an 18% premium issue, limiting near-term impact. The proceeds are allocated to long-term R&D, supporting growth. The change in counterparty to a PEF-affiliated SPC does not significantly affect credibility.
KOSDAQ Filing Information
[Correction of Description] Report on Major Events (Decision on Paid-in Capital Increase)